Author: Selina McKee

Campaigners call for NHS access to Orkambi as MP inquiry gets underway

Patients and campaigners took to the streets in London yesterday demanding NHS access to Vertex’ cystic fibrosis drugs, following a public hearing on the situation ordered by MPs.

Allergan’s rapastinel fails to hit key targets in depression trials

Allergan’s rapastinel has failed to hit its primary endpoints in three late-stage studies assessing its potential as an adjunctive treatment for depression.

Vertex’ three-drug CF combo hits PhIII targets

Vertex’ three-drug cystic fibrosis regimen – combining the investigational next-generation corrector VX-445 with Kalydeco (ivacaftor) and tezacaftor – has achieved primary endpoints of two Phase III studies in patients the condition.

BMS’ largest shareholder not in favour of Celgene deal

Bristol-Myers Squibb’s planned $74-billion purchase of Celgene has hit a significant obstacle after its largest institutional shareholder said it did not back the deal.

NHS to pilot new diabulimia service

NHS patients are set to receive therapy to “counteract the impact of harmful social media” as part of a new service designed to treat the rare eating disorder diabulimia.